Demographic table for the nondiseased and COPD cohorts
| Nondiseased control aged ≤40 years | Nondiseased control aged >40 years | COPD | |
| Subjects | 26 | 25 | 446 |
| Age years | 22 (20–23) | 63 (61–64) | 75 (68–80) |
| Male | 10 (38.5) | 12 (48.0) | 426 (96.2) |
| BMI kg·m−2 | 22.0 (21.0–24.0) | 24.0 (20.6–26.0) | 21.5 (18.7–23.8) |
| Smoking status | |||
| Current smoker | 0 (0.0) | 4 (16.0) | 303 (67.9) |
| Ex-smoker | 1 (3.8) | 3 (12.0) | 139 (31.2) |
| Never-smoker | 25 (96.2) | 18 (72.0) | 4 (0.9) |
| Smoking history pack-years | 0 (0–0) | 44 (33–53) | 50 (38–65) |
| FEV1 % pred | 96.5 (85.3–107.8) | 93.5 (84.0–97.8) | 45.0 (33.6–59.0) |
| FEV1/FVC % pred | 86.6 (82.3–93.2) | 78.6 (75.0–84.7) | 50.4 (41.2–59.5) |
| Number of exacerbations in the year preceding study entry | |||
| 0–1 | NA | NA | 293 (65.7) |
| >1 | NA | NA | 153 (34.3) |
| Hospitalisation in the year preceding study entry | |||
| Yes | 208 (46.6) | ||
| No | 238 (53.4) | ||
| COPD assessment test | NA | NA | 14 (9–19) |
| Blood eosinophil count ×109 cells·L−1 | NA | NA | 0.12 (0.00–0.29) |
| Total IgE IU·mL−1 | NA | NA | 24.5 (5.0–119.3) |
| Treatment | |||
| SAMA/SABA | 125 (28.0) | ||
| LAMA | 29 (6.5) | ||
| LAMA/LABA | NA | NA | 43 (9.7) |
| LABA/ICS | 115 (25.8) | ||
| LAMA/ICS | 18 (4.0) | ||
| LAMA/LABA/ICS | 116 (26.0) |
Data are presented as n, median (interquartile range) or n (%). BMI: body mass index; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; SAMA: short-acting muscarinic antagonist; SABA: short-acting β-agonist; LAMA: long-acting muscarinic antagonist; LABA: long-acting β-agonist; ICS: inhaled corticosteroid; NA: not applicable.